[Conservative drug therapy of neurogenic bladder disorders].
Today neuropharmacas are a helpful part in the conservative treatment of the neurogenic bladder disorders. They are, or course, no "wonder-drugs" and usually lead to an improvement only of the troubles, but rarely to complete cure. If monotherapy does not lead to the results wanted, one should combine drugs of the same of similar effects but with different pharmacologic targets. A real progress was reached through alpha-receptor-blockers, whose use has, especially in children with myelomeningocele, changed the therapeutic concept in favour of a largely conservative treatment. We already know a number of substances that in one way or other influence the muscles of the bladder and the bladder outlet. If only part of them will reach clinical usage, it can be assumed that the pharmacotherapy will become even more meaningful in the treatment of neurogenic bladder disorders.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000187:drug effects; D003975:Diazepam / Q000627:therapeutic use; D004629:Emepronium / Q000627:therapeutic use; D005422:Flavoxate / Q000627:therapeutic use; D006801:Humans; D001743:Urinary Bladder / Q000294:innervation; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D014554:Urination; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D004629:Emepronium; D005422:Flavoxate; D005680:gamma-Aminobutyric Acid; D003975:Diazepam
Die konservative medikamentöse Therapie neurogener Blasenstörungen.